![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61K 39/00 | (2006.01) |
C12P 21/08 | (2006.01) | ||
C07K 16/00 | (2006.01) | ||
A61P 35/00 | (2006.01) |
(11) | Number of the document | 2758073 |
(13) | Kind of document | T |
(96) | European patent application number | 12833767.2 |
Date of filing the European patent application | 2012-09-24 | |
(97) | Date of publication of the European application | 2014-07-30 |
(45) | Date of publication and mention of the grant of the patent | 2018-10-31 |
(46) | Date of publication of the claims translation | 2019-01-10 |
(86) | Number | PCT/US2012/056886 |
Date | 2012-09-24 |
(87) | Number | WO 2013/044215 |
Date | 2013-03-28 |
(30) | Number | Date | Country code |
201161538454 P | 2011-09-23 | US | |
201261597409 P | 2012-02-10 | US | |
201261692978 P | 2012-08-24 | US |
(72) |
GURNEY, Austin L., US
SATO, Aaron Ken, US
BOND, Christopher John, US
|
(73) |
OncoMed Pharmaceuticals, Inc.,
800 Chesapeake Drive, Redwood City, CA 94063,
US
|
(74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
(54) | VEGF/DLL4 surišantys agentai ir jų panaudojimas |
VEGF/DLL4 BINDING AGENTS AND USES THEREOF |
Payment date | Validity (years) | Amount | |
2024-08-09 | 13 | 289.00 EUR |
2025-09-24 |